Literature DB >> 9177370

Predictors of early remission of hyperthyroidism in children.

N S Glaser1, D M Styne.   

Abstract

Children with hyperthyroidism often require prolonged courses of antithyroid medication to achieve remission, and long-term compliance is problematic. To determine which clinical and laboratory features predict early remission, we reviewed the records of 191 patients less than 19 yr old with Graves' disease. We compared patients achieving remission within 2 yr (group 1, n = 27) with those who completed more than 2 yr of medical therapy but did not achieve a remission (group 2, n = 79). Patients who were in neither of the above categories (n = 85) were excluded from the statistical analysis. Variables that were measurable at the time of diagnosis, recorded in more than 50% of the study population and associated with early remission in the univariate analysis (P < or = 0.05), were entered into a stepwise multiple logistic regression analysis. Variables retaining a significant association with early remission (P < 0.05) were considered independent predictors of early remission. Patients achieving early remission were older (mean, 12.5 vs. 10.9 yr, P = 0.039) and had higher body mass indexes (BMI, 19.0 vs. 16.6, P = 0.002), higher BMI SD scores (-0.03 vs. -0.60, P = 0.004), lower heart rates (110 vs. 121, P = 0.023), smaller goiters (group 1: 60% with moderate/large goiter; group 2: 83%, P = 0.050), lower platelet counts (272 vs. 339 K/microL, P = 0.006), lower serum T4 and T3 concentrations at presentation (T4: 18.3 vs. 22.5 microg/dL, P = 0.015; T3: 439 vs. 613 ng/dL, P = 0.008), and were less likely to have a positive test for thyroid stimulating Igs (group 1: 50% vs. group 2: 93%, P = 0.008). Regression analysis identified BMI SD score and goiter size as independent predictors of early remission (P < 0.05). Eighty-six percent of patients with BMI SD score above -0.5 SD and minimal/small goiters achieved early remission, compared with 13% of those with BMI SD score below -0.5 SD and moderate/large goiters. We conclude that, of multiple clinical and laboratory variables associated with early remission, BMI SD score and goiter size are independent predictors. Algorithms employing these two variables can be used to facilitate counseling of patients and expedite therapeutic decisions.

Entities:  

Mesh:

Year:  1997        PMID: 9177370     DOI: 10.1210/jcem.82.6.3986

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  EANM procedure guidelines for therapy of benign thyroid disease.

Authors:  Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

Review 2.  The treatment of Graves' disease in children and adolescents.

Authors:  Hae Sang Lee; Jin Soon Hwang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2014-09-30

Review 3.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

4.  Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism.

Authors:  S Namwongprom; P Dejkhamron; K Unachak
Journal:  J Endocrinol Invest       Date:  2020-06-24       Impact factor: 4.256

5.  Adverse events associated with methimazole therapy of graves' disease in children.

Authors:  Scott A Rivkees; Kerry Stephenson; Catherine Dinauer
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-07

Review 6.  Juvenile thyrotoxicosis; can we do better?

Authors:  G Birrell; T Cheetham
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

7.  Ophthalmopathy in childhood Graves' disease.

Authors:  W Chan; G W K Wong; D S P Fan; A C K Cheng; D S C Lam; J S K Ng
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

8.  "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.

Authors:  M C Vigone; E Peroni; M Di Frenna; S Mora; G Barera; G Weber
Journal:  J Endocrinol Invest       Date:  2019-11-12       Impact factor: 4.256

Review 9.  Graves disease in childhood: a review of the options for diagnosis and treatment.

Authors:  Jorg Dötsch; Wolfgang Rascher; Helmuth G Dörr
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Surgical treatment of Graves' disease: evidence-based approach.

Authors:  Peter Stålberg; Anna Svensson; Ola Hessman; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.